<u>Biomarker, Imaging, & Quality of Life Studies Funding Program (BIQSFP)</u> http://biqsfp.cancer.gov/</u>

Department of Health and Human Services

Participating Organizations

National Institutes of Health (NIH) http://www.nih.gov/

Components of Participating Organizations

National Cancer Institute (NCI) http://www.nci.nih.gov/

Key Dates

Release Date: December 15, 2008; revised 4/1/10, 4/1/11, 4/1/12, 5/1/13, 12/23/13

<u>Submission Date:</u> There is no specific date for parent Clinical Trial Concept and BIQSFP study proposal submission to the Cancer Therapy Evaluation Program (CTEP) or the Division of Cancer Prevention (DCP).

Evaluation Process: The appropriate NCI Scientific Steering Committee (SSC) or external reviewers via CTEP/DCP if there is no appropriate SSC, evaluate and recommend the parent Clinical Trial Concept along with the Biomarker, Imaging and Quality of Life Studies proposal and/or Cost-Effectiveness Analysis (CEA) endpoint, during scheduled SSC meetings for concept review. BIQSFP proposals for funding of INTEGRAL biomarker, imaging, and/or Quality-of-Life (QOL) studies must be submitted concurrently with the parent concept. INTEGRATED biomarker, imaging, and/or QOL studies along with CEA study applications must be submitted after parent concept approval and must be received within four months (16 weeks) of notification of parent concept approval.

Scientifically meritorious BIQSFP proposals that are recommended by SSCs (or CTEP/DCP as applicable) are presented by NCI Program Staff to the Clinical and Translational Research Operations Committee (CTROC) for prioritization and approval at their bimonthly meetings. CTROC makes final funding recommendations. The Clinical Trials and Translational Research Advisory Committee (CTAC) periodically reviews the approved funding portfolio, providing strategic oversight and advice.

Expiration Date: December 31, 2014

The NCI Cooperative Groups will become the NCI National Clinical Trials Network (NCTN) effective March 1, 2014. In addition, the Division of Cancer Prevention's (DCP) Community Clinical Oncology Program (CCOP), Minority-Based CCOPs (MB-CCOPs) and their Research Bases will transition into the NCI's Community Oncology Research Program (NCORP) in the fall of 2014 and are referenced as CCOP Network/NCORP in this Announcement.

It is anticipated that the BIQSFP Announcement will be reissued in subsequent years.

I. Key Changes with Revised Announcement:

- A. NCI Cooperative Groups change to NCTN effective March 1, 2014.
- B. <u>INTEGRATED</u> biomarker, imaging, and/or QOL studies along with CEA study applications **must** be submitted after parent concept approval and must be received within four months (16 weeks) of notification of parent concept approval.
- C. Integrated studies will no longer be eligible for consideration as exceptions (see Page 7).

- D. NCTN/CCOP Network/NCORP investigators are encouraged to explore options for reducing the cost of assays and tests to be supported by BIQSFP funding. Cost sharing with other funders will have a positive impact on the evaluation (see Page 9).
- E. For all BIQSFP applications, the signature of the institutional business official will no longer be required at the time of initial submission of the total composite budgets (see Page 9).

II. Overview and Summary

The Division of Cancer Treatment and Diagnosis (DCTD) and the Division of Cancer Prevention (DCP), National Cancer Institute (NCI), invite funded NCTN groups and funded CCOP Network/NCORP to apply for funding to support biomarker, imaging, and quality of life studies as well as CEA proposals, all of which are associated with NCI clinical trial concepts

III. Purpose

As part of its Prioritization and Scientific Quality Initiatives, the NCI Clinical Trials Working Group (CTWG) recommended establishing a funding mechanism and prioritization process for correlative studies and quality of life studies that are incorporated into the fundamental design of a clinical trial and are not currently supported by the U10 funding mechanism. The purpose of the BIQSFP is to ensure that the most important, scientifically meritorious biomarker, imaging, and quality of life studies or CEA can be initiated in a timely manner in association with appropriate clinical trials.

Targeted biological studies, imaging, and quality of life studies embedded in clinical trials should have the potential to modify standard of practice. The tests/assays must be reliable and provide interpretable answers that are of benefit to patients leading to validation of targets, reduction of morbidity, prediction of treatment effectiveness, enhanced clinical trial design, identification of populations that may better benefit from treatment, and improvements in clinical trial accrual and retention.

In 2010, the NCI Clinical Trials and Translational Research Advisory Committee (CTAC) recommended the addition of Cost-Effectiveness Analysis (CEA) to the BIQSFP. The purpose of CEA is to ensure that the most important cost-effectiveness analyses can be conducted in association with appropriate NCI-sponsored clinical trials.

IV. Mechanism of Support

BIQSFP is managed through the Coordinating Center for Clinical Trials (CCCT) in the NCI Office of the Director (OD).

For the FY 2014 BIQSFP Announcement, the number of anticipated awards is contingent upon the availability of funds and the number of meritorious proposals submitted. NCI committed \$10M to BIQSFP funding in FY 2013. Applicants may submit more than one trial concept with biomarker, imaging, quality of life studies or a CEA, provided they are scientifically distinct. However, both the scientific merit of the parent clinical trial concept and the merit of the biomarker, imaging, quality of life study, or CEA study must be approved by the appropriate review entity (SSC, CTEP or DCP) in order to be eligible for the BIQSFP funding.

V. Requirements and Definitions

A. Eligible trial types for BIQSFP funding are:

- Trials conducted by NCTN groups and CCOP Network/NCORP
- Phase 3 treatment trials with integral or integrated biomarker or imaging studies, and/or quality of life studies.
- Phase 3 cancer prevention and QOL clinical trials with integral or integrated biomarker or imaging studies, and/or QOL studies.

- Large (≥100 patients), randomized phase 2 treatment trials with integral or integrated biomarker or imaging studies.
- For CEA, the parent concept must be a randomized phase 3 clinical trial with a comparator arm.
- B. <u>Treatment Trials</u> test the effectiveness of new treatments or new ways of using current treatments in people who have cancer. The treatments tested may include new drugs or new combinations of currently used drugs, new surgery or radiation therapy techniques, and vaccines or other treatments that stimulate a person's immune system to fight cancer.

 Combinations of different treatment types may also be tested in these trials.

 (NCI Fact Sheet 4/10)
- C. <u>Cancer Prevention Trials</u> test new interventions that may lower the risk of developing certain types of cancer. Most cancer prevention trials involve healthy people who have not had cancer; however, they often only include people who have a higher than average risk of developing a specific type of cancer. Some cancer prevention trials involve people who have had cancer in the past; these trials test interventions that may help prevent the return (recurrence) of the original cancer or reduce the chance of developing a new type of cancer.

 (NCI Fact Sheet 4/10)
- D. Quality-of-Life (Supportive Care) Trials focus on the comfort and quality of life of cancer patients and cancer survivors. New ways to decrease the number or severity of side effects of cancer or its treatment are often studied in these trials. How a specific type of cancer or its treatment affects a person's everyday life may also be studied.
 (NCI Fact Sheet 4/10)

Treatment trials are submitted to CTEP for evaluation by the appropriate NCI Disease-Specific Scientific Steering Committee.

Cancer prevention and QOL trials are submitted to DCP for evaluation by the appropriate NCI Scientific Steering Committee.

VI. Biomarker and Imaging Studies

Two types of biomarker and imaging studies are eligible for consideration – <u>integral</u> and <u>integrated</u>.

A. Integral Studies - Defined as tests that must be performed in order for the trial to proceed. Integral studies are inherent to the design of the trial from the onset and must be performed in real time for the conduct of the trial. Integral biomarkers require a CLIA-certified lab.

Integral studies have the highest funding priority.

Eligible categories of integral studies and examples are as follows:

- Tests to establish eligibility e.g., ERCC-1 to determine protocol eligibility for patients with gastric cancer or imaging assessment of hypoxia for trials of drugs effective in hypoxic tissues such as tirapazamine
- Tests for patient stratification e.g., measurement of 18qLOH and MSI for assignment of risk in stage 2 colon cancer
- Tests to assign patients to a treatment arm of a trial, including surrogate endpoints for assignment of treatment during a trial – e.g., FLT3/ITD ratio for assignment of pediatric AML patients to a study arm; eradication of the bcr-abl clone in CML to determine whether to continue treatment; FDG-PET scan after initial course of therapy to assess

- early response to determine whether to continue treatment where third-party payers would not cover the cost
- Non-reimbursable imaging tests to measure a primary endpoint or to stratify patients based on imaging response – e.g. PET scans for non-Hodgkin's lymphoma response to chemotherapy
- B. Integrated Studies Defined as tests that are clearly identified as part of the clinical trial from the beginning and are intended to identify or validate assays or markers and imaging tests that are planned for use in future trials. Integrated studies in general should be designed to test a hypothesis, not simply to generate hypotheses. The number of integrated assays/tests performed should be sufficient to obtain scientifically valid outcomes during the trial and include complete plans for specimen collection, laboratory measurements, proposed cutpoints, and statistical analysis. One example would be predictive biomarker assays that are measured either *in vitro* or *in vivo* where the assay result is not used for eligibility, treatment assignment, or treatment management in the current trial; a second example would be the use of an imaging test to detect biologic modification of the target but where the image is not used as a primary study endpoint.

C. Criteria for Review of Biomarker and Imaging Studies

Prioritization and evaluation criteria include:

- The strength of the preliminary data for both test utility and performance characteristics including cutpoints.
- The potential of the test to change practice and have high impact on patient care (e.g.; the impact of the test itself or the change of therapy indicated by the results of the trial).
- The ability of the test to yield well defined and validated interpretations that will guide decision-making.
- The extent of standardization of the tests as to be transferable to the non-research setting.
- The adequacy of the process for specimen collection or image acquisition including feasibility data.
- A description of potential cost-sharing approaches that can be developed with entities that would eventually commercialize the test.

Clinical assays that are used to assign or significantly modify a patient's treatment in the proposed clinical trial must have undergone rigorous <u>analytic validation</u> and sufficient <u>clinical validation</u> to warrant inclusion in a clinical trial. Such assays will ordinarily be performed in CLIA-accredited laboratories and will need FDA review as well.

It is not intended that any priority or particular level of merit is assigned to one criterion over another but rather the proposals are evaluated based on the totality of the information and strength of the data.

Applications for Biomarker studies will include a completed Biomarker Study Checklist, Budget, and Budget Justification. Applications for Imaging studies will include a completed Imaging Checklist, Budget, and Budget Justification.

VII. Quality of Life (QOL) Studies

QOL studies can be <u>integral</u> or <u>integrated</u> tests, assays, and/or tools. They must be part of the clinical trial design from the beginning (assessments conducted while the trial is open). They are intended to inform on treatment options and side effects by validating the biological and functional clinical correlates of patient–reported outcome (PRO) data. They may also

include biomarker assays and imaging tests that could be used for decision making in future trials.

Currently, DCP funds quality of life studies that obtain information for use in patient-physician decision making that help the patient prepare for and interpret the treatment experience. Examples of this DCP support may include studies where differences between treatments in survival or other disease-related endpoints are expected to be minimal or when treatment arms represent very different treatment scenarios. Assessments may include, but are not limited to, qualitative data, toxicity impact, convenience, psychosocial outcomes and function.

A. Eligible categories of quality of life studies and examples include:

- QOL studies to obtain additional information for use in patient—physician decision making or to help the patient prepare for and interpret the treatment experience when the collection of QOL data requires resources beyond the usual cancer control credits or per case reimbursement.
- Studies that validate measures previously tested in smaller studies. QOL measures that
 have been piloted in smaller studies and are supported by preliminary data require full
 validation in a phase 3 trial. This includes evaluating patient reported outcomes (PRO)
 as complementary adjuncts to clinician-assessed outcomes for measuring toxicity (e.g.,
 adverse events as measured by Common Toxicity Criteria).
- Studies in the PRO measurement field with the integration of modern measurement
 theory for the development of brief, precise, and valid PRO measures. These
 advancements provide an examination of the benefits of integrating these measures,
 including electronic data capture, into clinical trials. Examples of studies that fall into this
 category may include: computer-based testing, experience sampling, and multiple brief
 symptom assessment (as opposed to infrequent and lengthier assessment).

There is growing interest in the role of objective measures such as biomarkers, imaging studies, and measures of activity such as pedometers and actigraphs that can further inform symptoms, QOL assessments, and selected measures that validate PRO data such as:

- Studies that provide "objective" correlates to self-report measures that are not easily supported through funding for clinical trials. Concurrent collection of an "objective" test along with a performance measure provides stronger data when following patients on a symptom management or quality of life trial. Examples of studies in this category may include: enhancing measures that validate patient self-report of fatigue or physical function with objective actigraphy; and neuropsychological testing in studies of cognitive effects from therapy, or in following patients with brain tumors or metastases.
- Studies that are "predictive" measures with testable hypothesis(es) and a high likelihood to give validated interpretations, and correlative measures to predict morbidity, safety, pathophysiologic mechanisms of symptom expression, and/or treatment efficacy and genetic determinates of symptom expression, quality of life endpoints and treatment efficacy. Examples of these study measurements may include: cytochrome P450 metabolism; cytokine analyses; pharmacokinetic studies for drug interactions; neuroendocrine studies, and fMRI for cognitive changes.

B. Criteria for Review of Quality of Life Studies

Prioritization and evaluation criteria include:

- The potential to impact patient morbidity or quality of life with clinically meaningful benefit.
- The potential to move science forward in cancer related quality of life by adding critical knowledge.

- The strength of the preliminary data supporting the hypothesis(es) to be tested and methods proposed.
- A clearly defined process for data and specimen collection.
- A statistical plan with adequate power for testing the quality of life correlative study hypothesis(es).
- Measures that are reliable, valid and appropriate to the population of interest.
- Feasibility of proposal such that completion can be accomplished efficiently and in a reasonable time frame.

VIII. Cost-Effectiveness Analysis (CEA) Studies

Cost-Effectiveness Analysis (CEA) provides useful information to help health care payers manage the use of costly medical technologies in order to maximize the health of their patient populations when facing constrained budgets, and to clinicians and patients to help guide treatment decisions based on CEA's unique endpoints, perspectives (e.g., societal, clinical, or third-party), and time horizon (e.g., within trial or long-term survivorship). To be most useful to decision-makers, CEA of new cancer therapies must have maximal feasibility, be timely, and have high internal validity.

Conducting a CEA alongside a clinical trial can achieve these goals and also offers the benefit of efficiency by utilizing the existing structure of clinical trials to collect additional data for the economic analysis. It is not required that a CEA proposal be included with each clinical trial concept submitted. However, in some instances the addition of CEA may be recommended during evaluation review of the clinical trial concept.

The CEA evaluation criteria are intended to help guide the selection of cancer clinical trials that warrant additional funds for a CEA. The CEA study should be a secondary endpoint of the parent concept. SSCs evaluate CEA proposals paired with clinical trial concepts through their concept evaluation and prioritization process. SSCs will make use of ad hoc CEA expert(s), including resources available at the NCI, to evaluate CEA proposals included in clinical trial concepts.

Criteria for Review of CEA Proposals

Researchers should consider pairing a CEA proposal to phase 3 clinical trials when the following conditions are met:

- The results of a phase 3 clinical trial are expected to substantially influence clinical practice.
- The cost-effectiveness study would be of high impact judged by substantial budget implications for health care systems, either in terms of overall cost savings or added costs to the system.
- It is feasible to conduct a high quality CEA as part of the clinical trial. Specific issues to consider include:
 - The comparator arm should be relevant to current clinical practice.
 - The trial should be of sufficient duration, with respect to follow-up of patient outcomes, that consequences of interest to economic evaluation can be captured either directly or through modeling.
 - There is reasonable statistical power for the key cost-effectiveness analysis.
- Because of high cost of the experimental treatment, there is a reasonable degree of uncertainty regarding the outcome of the CEA even if the clinical outcome favors the experimental treatment.

Modeling is a pivotal part of the CEA proposal. CEA proposals should describe the general type of model that will be used. If a model is to be developed, the expertise of model developer, timeline for model development, calibration, and validation (if relevant) must be included in the proposal. This may include but not be limited to all model inputs that are needed and sources for these inputs,

what provisions need to be made to document model structure, assumptions, data inputs, parameter estimation, intermediate and final outputs so that replication of the CEA would be possible by an external analyst.

CEA proposals included in phase 3 clinical trial concepts should be developed by NCTN/CCOP Networks/NCORPs. When NCTN/CCOP Networks/NCORPs choose to submit a CEA proposal, it must be submitted after parent concept approval but must be received within four months (16 weeks) of their notification of the parent concept approval.

IX. Studies Ineligible for BIQSFP Funding

- Studies that do not meet the definitions for eligible trials [e.g., phase 1 concepts, small (<100 patients) randomized & all non-randomized phase 2 concepts, studies involving toxicity screens on animals].
- Studies that are still within the discovery phase or pre-clinical development stage focusing on assay development.
- Studies that can be conducted in the future on stored specimens (retrospective studies), except if the results are critical to the stated primary or secondary objectives of the trial.
- Studies eligible for DCP Cancer Credits.
- Cohort studies, screening studies, or longitudinal observational studies.
- Studies that include assays, tests, or tools that are standard of care and normally reimbursed by third-party payers.
- Integrated studies submitted more than four months (16 weeks) following NCTN/CCOP Network/NCORP notification of parent concept approval.

Exceptions

While the primary purpose of this funding is for newly developed concepts, in some circumstances, large randomized phase 2 and any phase 3 protocols with an INTEGRAL component, and/or cancer prevention or QOL protocols that are still in development may be considered for the BIQSFP if they are of exceptional clinical importance and address the evaluation criteria and **Performance**Standards. It is recommended that these be discussed with CTEP or DCP Program Staff prior to submission to determine eligibility. Integrated studies will no longer be eligible for consideration as exceptions. Only integral studies will be eligible for exceptions.

X. BIQSFP Proposal Package & Submission

BIQSFP application packages requesting funding for **INTEGRATED** biomarkers, QOL, and imaging studies associated with phase 2 and 3 treatment trials (CTEP) or phase 3 prevention or symptom management trials (DCP) and proposals for CEA studies are no longer allowed at the time of submission of the parent clinical trial concept to the CTEP/DCP PIO for evaluation by SSCs. Instead, NCTN/CCOP Network/NCORP investigators may only submit a <u>one-time</u> application for studies that fit the definition of an "integrated study" or a CEA study for evaluation after parent concept approval. The INTEGRATED application must be received within four months (16 weeks) of notification of parent concept approval by the SSC.

A. BIQSFP Proposal Package What is required?

- A cover letter signed by the NCTN/CCOP Network/NCORP Chair indicating submission of a biomarker, imaging, quality of life, and/or CEA study in response to the BIQSFP announcement. **The cover letter should include**:
- The title(s) of the BIQSFP project(s).
- Brief description of the project(s) indicating whether the study(s) is integral or integrated.
- Type of study(s) proposed (biomarker, imaging, quality of life, and/or CEA).

- Total budget figure requested for each project (biomarker, imaging, QOL, CEA).
- Duration of the study.
- Detailed budget as described in the Budget Preparation section (below).
- The parent clinical trial concept with the biomarker, imaging, QOL, and/or CEA study embedded (for evaluation by SSCs or where appropriate, CTEP or DCP).
- B. Biomarker: A separate document is required describing the characteristics and performance of each biomarker assay test proposed for funding, and its role in the trial. Applicants should refer to the Study Checklist for Large, Randomized Phase 2 or Phase 3 Trials with Biomarker Assays (see attached) for instructions on what information is needed. This section is not to exceed five (5) pages for each assay. Integral and integrated studies require a separate BIQSFP Proposal Package as indicated above.

For additional explanations and definitions, investigators are also encouraged to visit

Performance Standards Reporting Requirements for Assays in Clinical Trials at:

http://www.cancerdiagnosis.nci.nih.gov/scientificPrograms/pacct/PACCT_Assay_Standards_Document.pdf.

Additional information regarding validation of integral biomarkers can be found at NCI's Cancer Diagnosis Program (CDP) website: http://www.cancerdiagnosis.nci.nih.gov/diagnostics/templates.htm

For BIQSFP study proposals containing assays that are not fully developed, applicants can refer to NCI's Clinical Assay Development Program (CADP) website for guidance regarding assay validation: http://cadp.cancer.gov.

- C. Imaging: A separate document is required describing the characteristics and performance of each imaging test proposed for funding, and its role in the trial. Applicants should refer to the Study Checklist for Large, Randomized Phase 2 or Phase 3 Trials with Imaging Assays (see attached) for instructions on what information is needed. This section is not to exceed five (5) pages for each imaging test. If both integral and integrated studies are proposed within the same concept being submitted, each study will require a separate BIQSFP Proposal Package as indicated above.
- D. Quality of Life: A separate document is required describing the characteristics and performance of <u>each</u> measure that validates a QOL assessment and/or an instrument proposed for funding, and its role in the trial. Applicants should refer to the *Study Checklist for Randomized Phase 3 Trials with QOL Components* (see attached) for instructions on what information is needed. This section is not to exceed <u>five (5) pages for each assay or test</u>. If both integral and integrated studies are proposed within the same concept being submitted, each will require a separate BIQSFP Proposal Package as indicated above.
- E. Cost-Effectiveness Analysis: A separate document is required describing the rationale and justification of the CEA proposal for funding. The CEA proposal should be a secondary endpoint of the parent study. Applicants should refer to the Study Checklist for Randomized Phase 3 Clinical Trials with a Comparator Arm and Cost-Effectiveness Analysis (CEA) Component(s) (see attached) for instructions on what information is needed. This section is not to exceed eight (8) pages. The CEA budget justification should include:
 - Evidence of institutional capacity and/or experience in health economic analysis;
 - Evidence of training, expertise and/or experience in health economic analysis and related expertise (e.g. instrument development, medical abstraction, administrative coding, cost analysis, etc.) by the proposed investigator(s) and/or staff;
 - An activity analysis for each year of the proposed study, i.e. how much and what kind of resources/personnel will be required for relevant phases of the study in each year, e.g. model development, data abstraction, data acquisition, analysis, etc.;

• Evidence that the timeframe of the proposed CEA study is consistent with the timeframe of the parent study. For example, will data abstraction instruments needed for the CEA be developed and validated in time for data acquisition in the parent trial? Will results from the parent trial on health outcomes that are necessary inputs to the CEA be available when needed? If there is a delay in the availability of trial outcomes beyond the timeframe of the proposed CEA study, what provisions will be made to ensure that the CEA will be completed?

F. Budget Preparation

- All BIQSFP study proposals must include a budget at the time of submission that clearly details the costs (Direct and Indirect) for each of the biomarker, imaging, quality of life, and/or CEA study proposal submitted.
- A total composite budget must be provided for the entire cost of the BIQSFP project. The budgets for the project should use the Form PHS 398 along with a narrative justifying each requested cost (http://grants.nih.gov/grants/funding/phs398/phs398.html).
- Covered BIQSFP costs may include but not be limited to procurement of and completion of research assays on blood or tissue, central pathology or image reading, and shipping.
 Costs associated with QOL assessments that are conducted as part of CEA may be included.
- Costs for the PI of the clinical trial concept/study and/or Cooperative Group/CCOP leadership are <u>not</u> covered under the BIQSFP program.
- NCTN/CCOP Network/NCORP investigators are encouraged, where applicable, to explore
 options for reducing the cost of assays and tests to be supported by BIQSFP funding.
 These cost sharing options might include billing third party payers or partial funding from
 commercial partners, or choosing between academic vs. commercial labs. Investigators'
 use of commercially available laboratory tests may aid in reducing budgetary requirements.
 Cost sharing with other funders will have a positive impact on the evaluation.
- For all BIQSFP applications, the signature of the institutional business official will no longer be required at the time of initial submission of the total composite budgets. Institutional approval and sign-off will be required once the final funding has been approved by the NCI.
- **G.** A complete **Proposal Package**, including attachments, must be emailed via <u>pdf attachment</u> to the relevant Program office.

CCOP Network/NCORP non-treatment clinical trial proposals must be e-mailed to:

NCI DCP Protocol Information Office - ncidcppio2@mail.nih.gov
cc: Worta McCaskill-Stevens, MD, MS - wm57h@nih.gov
Ann O'Mara, Ph.D. - omaraa@mail.nih.gov

NCTN/CCOP Network/NCORP treatment clinical trial proposals must be e-mailed to:

NCI CTEP Protocol Information Office - PIO@ctep.nci.nih.gov cc: Margaret Mooney, M.D. - mooneym@ctep.nci.nih.gov

E-mail submissions must reference "BIQSFP" in the Subject line.

XI. Terms and Conditions for Funding

BIQSFP Administrative Supplements are provided annually via the parent U10 Cooperative Agreement for the study and will be administered by CCCT in conjunction with the appropriate NCI program (i.e., CTEP or DCP). All the terms and conditions of the of the parent U10 award apply to this funding. BIQSFP Administrative Supplement recipients will be required to provide an annual progress report to CCCT.

In some instances, the BIQSFP awards may be via subcontracts through Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.).

Funding is restricted for the purpose of the approved project. Similarly, any carryover requests for this award are limited to the approved project unless written approval is obtained in advance by the relevant NCI program official. Funding is dependent on continuance of the clinical trial protocol and adequate progress.

XII. Publication of BIQSFP-Funded Studies

Upon completion of BIQSFP-funded studies, publications should acknowledge the funding source as follows:

"This clinical study was supported in whole or in part by funding from the Biomarker, Imaging, & QOL Studies Funding Program (BIQSFP) awarded by the National Cancer Institute".

XIII. Inquiries

Questions regarding responsiveness of the proposed studies to the BIQSFP should be directed to the one of the following NCI Program Staff:

For CTEP:

Margaret M. Mooney, M.D. Chief, Clinical Investigations Branch National Cancer Institute 9609 Medical Center Drive Room 5W-412 Bethesda, MD 20892-9737 ROCKVILLE MD 20850-9737

Phone: 240-276-6560

Email: mooneym@ctep.nci.nih.gov

For DCP:

Worta J. McCaskill-Stevens, MD, MS Chief, Community Oncology and Prevention Trials Research Group

Head, Breast Cancer Prevention Division of Cancer Prevention National Cancer Institute 9609 Medical Center Drive

Room 5E-446

Bethesda, MD 20892

For non USPS mail (FedEx, UPS, etc.)

Rockville, MD 20850 Phone: 240-276-7075 Email: wm57h@nih.gov Ann M. O'Mara, Ph.D.

Head, Palliative Care Research

Community Oncology and Prevention Trials Research Group

National Cancer Institute

9609 Medical Center Drive

Room 5E-444

Bethesda, MD 20892

For non USPS mail (FedEx, UPS, etc.)

Rockville, MD 20850 Phone: 240-276-7050

Email: omaraa@mail.nih.gov

Questions regarding cancer imaging studies:

Lalitha K. Shankar, MD, PhD

Chief, Clinical Trials Branch

Cancer Imaging Program

Division of Cancer Treatment and Diagnosis

National Cancer Institute

9609 Medical Center Dr

Room 4W-346, MSC 9729

Bethesda, MD 20892-9729

[FedEx: Rockville, MD 20852-4910]

Phone: 240-276-6510 shankarl@mail.nih.gov

Questions regarding the prioritization, evaluation, and Administrative Supplements funding processes should be directed to:

Raymond A. Petryshyn, Ph.D.

Program Director

Coordinating Center for Clinical Trials

National Cancer Institute

9609 Medical Center Drive

Room 6W-608

Bethesda, MD 20892-9744

Phone: 240-276-6160 Fax: 240-276-7868

Email: petryshr@mail.nih.gov

Questions regarding Cost-Effectiveness Analysis should be directed to:

O. Wolf Lindwasser, Ph.D.

Program Director

Coordinating Center for Clinical Trials

National Cancer Institute

9609 Medical Center Drive

Room 6W-620

Bethesda, MD 20892-9744

Phone: 240-276-6160 Fax: 240-276-7868

Email: wolf.lindwasser@nih.govwolf.lindwasser@nih.gov

<u>'14 Study Checklist for Large Randomized Phase 2 and Any Phase 3 Trials with</u> <u>BIOMARKER ASSAYS</u>

INSTRUCTIONS: For <u>INTEGRAL</u> assay, respond to Items 1-7. For INTEGRATED assay, respond to Items 1, 2, 4-7.

Please submit a response to each of the criteria below and complete one Study Checklist and the Form PHS 398 Grant Budget Worksheets for <u>each</u> Biomarker endpoint.

<u>NOTE</u>: One-time <u>INTEGRATED</u> biomarker study applications must be submitted after parent concept approval and must be received within four months (16 weeks) of notification of parent concept approval. Subsequent NCI prioritization and approval for funding will be decided by CTROC after evaluation of the INTEGRATED study(s) by the respective SSC.

- 1. For an integral or integrated assay, indicate the role(s) of the biomarker assay in the trial:
 - A. Eligibility criterion
 - B. Assignment to treatment
 - C. Stratification variable
 - D. Risk classifier or score
 - E. Other (describe in detail)
- 2. Identify the specific individual(s) and laboratory(ies) who are being considered for conducting the assay(s) for the trial.
- 3. <u>Integral</u> laboratory assays used for clinical decision-making must be performed in a CLIA-certified facility. Provide the lab's CLIA number that is performing the <u>integral</u> biomarker study(ies) and the expiration date of the certificate.
- 4. Describe the assay:
 - A. Specify the analyte(s), technical platform, and sources of assay components (e.g., reagents, chips, and calibrators).
 - B. Describe the specimens, and anticipated methods for specimen acquisition, fixation or stabilization and processing.
 - C. Describe the scoring procedures and type of data to be acquired
 - quantitative/ continuously distributed
 - semi-quantitative/ordered categorical
 - qualitative/non-ordered categorical
- 5. Provide data on the clinical utility of the integral/integrated assay as it will be used in the trial:
 - A. Provide background information that justifies the use of this assay result as a marker for this trial. For example, if the integral marker will be used as a stratification or treatment-determining variable, data supporting its prognostic or predictive association with a main trial endpoint should be described or referenced.

Note: If the trial objectives include an evaluation of the association of the integral marker with a new clinical endpoint or factor not previously studied, the statistical section of the concept should explain how the magnitude of the association or effect will be measured and provide power calculations for any statistical tests that are planned.

- B. Describe the expected distribution of the biomarker in the study population.
- C. If cutpoints will be used, specify the cutpoint(s) and describe how these will be used in the trial). Provide the rationale for the cutpoint(s) selected. What proportion of subjects is expected to have values above and below the proposed assay value cutpoints? What magnitude of effect (e.g., treatment benefit) or outcome (e.g., prognosis) is expected for patients with assay results above and below the proposed cutpoint(s)?
- D. Describe under what conditions treating physicians and or patients will be able to access the biomarker assay results.
- 6. Provide data on the analytical performance of the assay.
 - A. For *in vitro* tests, describe the current status of studies defining the accuracy, precision, reportable range, reference ranges/intervals (normal values), turn-around time and failure rate of the assay <u>as it is to be performed in the trial</u>. Describe the use of positive and negative controls, calibrators, and reference standards for clinical assays. Describe any critical preanalytic variables. For guidance on regulatory requirements for laboratory assays please visit: http://www.cms.gov/CLIA/05 CLIA Brochures.asp.
 - B. If the assay will be performed at more than one site, describe how inter-laboratory variability in the measurements listed in 5A above will be assessed. Describe how these sources of variation will be minimized to maintain performance at all sites within acceptable limits and to prevent drift or bias in assay.
- 7. The Budget Justification should include a description of potential cost-sharing approaches for the assay (e.g., billing to third-party payers, partial funding from commercial partners, or choosing between academic vs. commercial labs, etc.) along with justification for the costs of academic vs. commercial laboratories.

8/08,3/09,3/10,3/11,3/12,4/13,11/13

<u>'14 Study Checklist for Large Randomized Phase 2 and Any Phase 3 Trials with IMAGING TESTS</u>

INSTRUCTIONS: Please submit a response to each of the criteria below and complete one Study Checklist and the Form PHS 398 Grant Budget Worksheets for <u>each</u> Imaging endpoint.

<u>NOTE</u>: One-time <u>INTEGRATED</u> imaging study applications must be submitted after parent concept approval and must be received within four months (16 weeks) of notification of parent concept approval. Subsequent NCI prioritization and approval for funding will be decided by CTROC after evaluation of the INTEGRATED study(s) by the respective SSC.

- 1. Indicate the role of the imaging test in the trial and whether it is INTEGRAL or INTEGRATED:
 - A. Eligibility criterion
 - B. Assignment to treatment
 - C. Stratification variable
 - D. Risk classifier or predictive and prognostic markers
 - E. Response assessment
 - F. Other (describe in detail):
- 2. Identify the specific individual(s) or imaging departments/sites that are being considered for conducting the imaging test for the trial.
- 3. Describe the imaging test:
 - A. Specify the imaging devices or imaging agents.
 - B. Describe any patient preparation procedures, as well as the procedures for imaging, analysis, and interpretation of the results.
 - C. Describe the scoring procedures and type of data to be acquired
 - quantitative/ continuously distributed
 - semi-quantitative/ordered categorical
 - qualitative/non-ordered categorical
- 4. Provide data on the clinical utility of the integral/integrated imaging test as it will be used in the trial:
 - A. Provide background information that justifies the use of this imaging test result as a part for this trial. For example, if the integral imaging test will be used as a stratification or treatment-determining variable, data supporting its prognostic or predictive association with a main trial endpoint should be described or referenced.

Note: If the trial objectives include an evaluation of the association of the integral marker with a new clinical endpoint or factor not previously studied, the statistical section of the concept should explain how the magnitude of the association or effect will be measured and provide power calculations for any statistical tests that are planned.

- B. Describe the expected distribution of the imaging study results in the study population.
- C. If cutpoints will be used, specify the cutpoint(s) and describe how these will be used in the trial). Provide the rationale for the cutpoint(s) selected. What proportion of subjects is expected to have values above and below the proposed imaging cutpoints? What magnitude of effect (e.g., treatment benefit) or outcome (e.g., prognosis) is expected for patients with imaging results above and below the proposed cutpoint(s)?

- D. Describe under what conditions treating physicians and or patients will be able to access the imaging test results.
- 5. Provide data on the analytical performance of the imaging test.
 - A. Describe the known performance characteristics of the imaging test. State and justify the limits of acceptable performance. Describe the use of positive and negative controls, calibrators, and reference standards for the imaging test.
 - B. If the imaging test will be performed at more than one site, describe how inter-facility variability in the measurements will be assessed. Describe how these sources of variation will be minimized to maintain performance at all sites within acceptable limits and to prevent drift or bias in imaging test results.
- 6. Provide the type and number of scans. Indicate if the scan is standard of care (SOC) or investigational: e.g., 300 MRIs (SOC): 100 patients x 3 per patient; 200 FDG PET/CTs (investigational for the proposed indication/time point): 100 patients x 2 per patient; 100 F-MISO PET/CTs (investigational): 100 patients x 1 per patient.
- 7. The Budget Justification should include:
 - A. Site/scanner qualification costs (usually done prior to patient enrollment in multi-center trials).
 - B. Technical costs for each type of scan (including facility use, scanner time costs, etc.).
 - C. Professional costs for each type of scan (*including cost for local radiologists / nuclear medicine physicians to interpret the images*).
 - D. Image transfer costs (includes network costs, shipping/mailing costs if physical media is used for transport).
 - E. Central imaging review costs (if central review is performed) for each type of scan.
 - F. Real time image review costs (if applicable) for each type of scan.
 - G. Image quality assurance costs (additional data QA costs on top of basic interpretation or central review costs).
 - H. Imaging agent and contrast material costs, for each type of scan: (*if imaging agent costs can be further broken down into categories such as agent manufacturing, transport, or storage costs, please provide those*).
 - I. Image storage costs (includes costs for long term storage of imaging data, archiving, backup systems, etc.).
 - J. Statistical support costs (can include costs for services such as a contracted statistical center).
 - K. Salary support costs (e.g. investigators, imaging technologists, research coordinators, study nurses, research assistants, etc.).

4/13,11/13

<u>'14 Study Checklist for Randomized Phase 3 Trials with Quality of Life</u> <u>(QOL) Components</u>

INSTRUCTIONS: Please submit a response to each of the criteria below. Please complete one Study Checklist and the Form PHS 398 Grant Budget Worksheets for each QOL endpoint.

<u>NOTE</u>: One-time <u>INTEGRATED</u> QOL study applications must be submitted after parent concept approval and must be received within four months (16 weeks) of notification of parent concept approval. Subsequent NCI prioritization and approval for funding will be decided by CTROC after evaluation of the INTEGRATED study(s) by the respective SSC.

- 1. State the HRQOL (health-related quality of life) hypothesis(es) and its scientific foundation. Specify the study endpoint(s).
- 2. Identify the HRQOL instrument(s) to be used to test each hypothesis, the basis for choosing each instrument, and the timing of the assessments.
- 3. For each instrument, document its validity, reliability, and responsiveness in the selected patient population. Specify the minimum important difference (MID) or metric for clinically-significant change.
- 4. For each instrument, identify whether it is INTEGRAL or INTEGRATED.
- 5. Describe any included *objective* correlates that enhance the patient-reported outcomes data (e.g. actigraphy, imaging, pulse ox, etc).
- 6. Identify any *biomarker or imaging* correlates of the patient-reported outcome measure(s) that will be collected (e.g., molecular, protein, other assays or tests).
- 7. Explain how patient non-compliance, missing data and/or early death may impact the analysis.
- 8. How will visually-challenged, non-English speaking patients be accommodated when completing the instrument(s)?
- 9. Describe the procedures for data collection and data monitoring including the training of data collection personnel.

3/09,3/10,3/11,3/12,11/13

<u>'14 Study Checklist for Randomized Phase 3 Clinical Trials with a Comparator Arm and Cost-Effectiveness Analysis (CEA) Component</u>

INSTRUCTIONS: Please submit a response to each of the elements below and complete the Form PHS 398 Grant Budget Worksheet.

<u>NOTE</u>: One-time <u>INTEGRATED</u> CEA study applications must be submitted after parent concept approval and must be received within four months (16 weeks) of notification of parent concept approval. Subsequent NCI prioritization and approval for funding will be decided by CTROC after evaluation of the INTEGRATED study(s) by the respective SSC.

- 1. Explain why it is necessary to conduct this CEA alongside the parent clinical trial. For example, explain why an independent modeling study conducted during or after the clinical trial is completed is not feasible and/or why it would be of lesser value in informing clinical practice and/or policy compared to a CEA conducted alongside the parent clinical trial.
- 2. Describe and justify the perspective of the CEA.
- 3. Explain the situations in which the outcomes of the clinical trial could substantially change clinical practice.
- 4. Describe the potential implication(s) of different outcomes of the trial on overall costs to the health care system, in terms of costs saved or costs added.
- 5. Briefly describe and justify the CEA study in terms of:
 - A. Trial population (in relationship to treatment population in community practice)
 - B. Intervention(s) and control therapy selected for the CEA
 - C. Question or hypothesis posed
 - D. Measure(s) of outcome for the CEA
 - E. Method of estimating costs
 - F. Modeling approach proposed (if appropriate; e.g., decision tree, Markov, micro-simulation, etc. Provide sources of documentation if using an existing model. If a model is to be developed, the expertise of model developer, timeline for model development, calibration, and validation (if relevant) must be included in the proposal. This may include but not be limited to all model inputs that are needed and sources for these inputs, what provisions need to be made to document model structure, assumptions, data inputs, parameter estimation, intermediate and final outputs so that replication of the CEA would be possible by an external analyst.)
 - G. Approach to characterizing uncertainty analysis
 - H. The time horizon and discount rates of the CEA. If the time horizon of the CEA exceeds that of the trial, describe the extrapolation or modeling approach that will be used.
- 6. Describe all data elements that will be collected for the CEA. This description should include:
 - A. A description of data elements that will already be collected as part of the protocol of the parent study and which additional data elements will need to collected.
 - B. A description of the data instrument development and validation process for new data elements.
 - C. A description of resources and personnel required for data collection and how the added data collection is consistent with the intended protocol of the parent study, i.e. is it logistically feasible and will not create and unreasonable additional burden.

- D. A description of any sources of data elements external to the parent protocol (e.g. linked or unlinked administrative data). If relevant describe external data sources and methods for obtaining estimates of unit cost. Provide information supporting whether unit cost estimates are relevant, consistent and valid.
- 7. Provide a power analysis to indicate that the sample sizes for health outcomes and economic data elements are sufficient to result in confidence intervals around the cost effectiveness ratio that render the results of the CEA useful to decision makers.
- 8. Describe any threats to the external validity of the study in relation to community practice.

3/10,3/11,3/12,1/13,11/13